期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 122, 期 11, 页码 4105-4117出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI42127
关键词
-
资金
- Swiss National Science Foundation
- National Research Center Frontiers in Genetics
- Bonizzi-Theler-Stiftung
- 7th EU program TORNADO
- Canadian Institute of Health Research
- Canadian Diabetes Association
- Wellcome Trust [081958/Z/07/Z]
- MRC [G0401641]
- NIH [ROI DKO71962-01]
- Diabetes UK
- European Union FP6 (SaveBeta)
- EU IMI FP7 program IMIDIA
- Islamic Development Bank
- Wellcome Trust [081958/Z/07/Z] Funding Source: Wellcome Trust
- MRC [G0401641] Funding Source: UKRI
- Medical Research Council [G0401641] Funding Source: researchfish
PPAR beta/delta protects against obesity by reducing dyslipidemia and insulin resistance via effects in muscle, adipose tissue, and liver. However, its function in pancreas remains ill defined. To gain insight into its hypothesized role in beta cell function, we specifically deleted Pparb/d in the epithelial compartment of the mouse pancreas. Mutant animals presented increased numbers of islets and, more importantly, enhanced insulin secretion, causing hyperinsulinemia. Gene expression profiling of pancreatic beta cells indicated a broad repressive function of PPAR beta/delta affecting the vesicular and granular compartment as well as the actin cytoskeleton. Analyses of insulin release from isolated PPAR beta/delta-deficient islets revealed an accelerated second phase of glucose-stimulated insulin secretion. These effects in PPAR beta/delta-deficient islets correlated with increased filamentous actin (F-actin) disassembly and an elevation in protein kinase D activity that altered Golgi organization. Taken together, these results provide evidence for a repressive role for PPAR beta/delta in beta cell mass and insulin exocytosis, and shed a new light on PPAR beta/delta metabolic action.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据